logo-loader

Radient to exhibit Onko-Sure diagnostic cancer test at ASCO meeting

Published: 16:25 18 May 2011 BST

no_picture_pai

Radient Pharmaceuticals (AMEX:RPC) announced Wednesday that it will exhibit its new, FDA-cleared Onko-Sure technology at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois, from June 3 - 6.

Onko-Sure, which has already been cleared by the US FDA, is a cancer test kit, designed to monitor and detect up to 14 different types of solid tumour cancers. The kit is available to both healthcare professionals and their patients.

"Participating in ASCO 2011 is another step forward in increasing awareness of Onko-Sure through outreach to key opinion leaders on a national and international level," said Radient's director of oncology, Dr. Afsaneh Motamed-Khorasani.

"Providing published clinical study results and our product's strengths at scientific conferences is a key component of building adoption rates for Onko-Sure globally."

The exhibition marks the third scientific conference Radient has attended in 2011. In January, the company presented its Onko-Sure technology at the BIO Asia Partnering Conference in Tokyo.

Just a month later, the company made a poster presentation on its lung cancer study results at the European Multidisciplinary Conference in Thoracic Oncology in Lugano, Switzerland.

Last year's ASCO annual meeting  was attended by over 30,000, and consisted of educational and scientific sessions, designed to introduce new information on the diagnosis and treatment of cancer patients.

Chesnara reports strong 2023 results with improved cash generation and...

Chesnara PLC (LSE:CSN) chief executive Steve Murray discusses the company's full-year results for 2023 with Proactive's Stephen Gunnion, describing them as strong and particularly highlighting £53 million in commercial cash generation and a dividend coverage of around 150%. The company has...

2 hours, 1 minute ago